Iovance (IOVA) Q4 2025 earnings review
A Spectacular Margin Turnaround Validates the Commercial Model
Iovance delivered an exceptionally strong Q4, reversing the margin collapse seen earlier in the year and proving that individualized cell therapy can be financially viable. Total revenue accelerated 30% sequentially to $86.8 million, bringing FY25 revenue to $263.5 million and achieving guidance. The real story, however, is the bottom line. After gross margins plummeted to 5.5% in Q2 due to manufacturing issues, they surged to 50% in Q4. This cost optimization, coupled with steady OpEx, drove Net Loss down to $71.9 million—its lowest level in over a year. The cash runway has been extended into Q3 2027, significantly reducing near-term dilution risk.
🐂 Bull Case
The transition to internalized manufacturing at the iCTC facility is working. Gross margin expanded from 5.5% in Q2 to 50% in Q4. With management promising further improvements in 2026, the unit economics are finally aligning with the company's long-term targets.
Amtagvi's real-world objective response rate (ORR) is tracking at ~44%, with a massive 52% ORR in patients with two or fewer prior lines. This data is successfully driving earlier patient referrals from community oncologists.
🐻 Bear Case
Proleukin sales spiked dramatically to $22 million in Q4 (up from $10 million in Q3). Because Proleukin is highly dependent on wholesaler stocking patterns, a portion of this may be inventory build rather than organic demand, setting up a potential Q1 2026 hangover.
Iovance is still working with the EMA to resubmit its Marketing Authorization Application (MAA) in 2026 after withdrawing it previously. This materially delays access to a major market and places the burden of near-term growth entirely on U.S. execution.
⚖️ Verdict: 🟢
Bullish. Management executed a flawless turnaround from a messy Q1/Q2. Accelerating revenue growth combined with a dramatic reduction in cash burn changes the fundamental thesis from a risky commercial bet to a scalable biopharma business.
Key Themes
Gross Margin Reversing from Collapse
The most critical data point in this report is the gross margin recovery. After falling to 10% in Q1 and 5.5% in Q2 due to patient drop-offs, out-of-spec products, and maintenance shutdowns, gross margin reached 43% in Q3 and 50% in Q4. This validates the Q3 strategic restructuring and the move to internalize all lifileucel manufacturing. Management expects margins to continue improving, tracking toward their historical target of >70%.
U.S. Amtagvi Sales Accelerating
U.S. Amtagvi sales reached ~$65 million in Q4, up from $58 million in Q3 and $43.6 million in Q1. Growth is accelerating as the Authorized Treatment Center (ATC) network matures. The introduction of community ATCs in late 2025 and the addition of a specialty pharmacy distribution channel are effectively unlocking new patient cohorts and mitigating the initial launch bottlenecks.
Proleukin Volatility Obscures True Run-Rate
Global Proleukin revenue jumped 120% sequentially to ~$22 million in Q4, up from $10 million in Q3. While management previously noted that Proleukin orders serve as a leading indicator for Amtagvi demand, this specific metric is heavily influenced by major wholesaler restocking. This creates a risk that Q4 top-line growth is artificially inflated by inventory timing rather than pure patient infusions.
NSCLC (Lung Cancer) Pipeline Validated
The pipeline narrative is shifting from melanoma to non-small cell lung cancer (NSCLC). The FDA granted Fast Track Designation for lifileucel in second-line advanced NSCLC. Interim data from IOV-LUN-202 shows a 26% ORR with median duration of response (mDOR) not reached at 25+ months. Compared to the standard of care (docetaxel: 12.8% ORR, 5.6 months mDOR), this is a potential game-changer. This market is roughly 7x the size of the current melanoma indication.
Sarcoma Representing a New Frontier
Iovance reported a 50% ORR in the first six evaluable patients for advanced undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS). They plan to commence a single-arm registrational trial in Q2 2026. This adds a tangible near-term clinical catalyst to the calendar for a rare disease with virtually no effective options.
Other KPIs
Decelerating. Total Q4 OpEx came in at $107.6M, a reduction from Q3 ($109.7M) and down significantly from Q2 levels. This reflects the successful implementation of the Q3 restructuring plan, which included a 19% workforce reduction. The company is extracting more revenue from a leaner corporate base.
Cash balance ended slightly lower than Q3's $307M, reflecting a drastically reduced net cash burn in the fourth quarter. The current treasury is sufficient to carry the company into Q3 2027, effectively neutralizing immediate equity offering fears.
Guidance
Accelerating/Improving. Pushing the runway into the third quarter of 2027 signals deep confidence in the forward margin profile and ongoing cost discipline, giving the company ample time to read out data for its NSCLC and Sarcoma trials without staring down a fiscal cliff.
Accelerating. While management did not provide a specific numerical target for 2026, they explicitly guided for continued gross margin and operating expense improvements in 2026 and 2027, driven by the complete internalization of manufacturing.
Stable. Following the Canadian approval in late 2025, Iovance anticipates regulatory decisions in the UK and Australia in the first half of 2026. The EMA MAA resubmission is planned for 2026, but the exact timing remains vague.
Key Questions
Proleukin Sales Breakdown
Q4 Proleukin sales doubled sequentially to $22 million. How much of this was driven by end-user clinical demand aligned with Amtagvi infusions versus major wholesalers placing bulk restocking orders?
EMA MAA Resubmission Mechanics
What specific data or virtual control arm analyses are required for the 2026 EMA MAA resubmission, and what gives you confidence this package will satisfy European regulators after the previous withdrawal?
Numerical 2026 Revenue Guidance
Given the stabilization of the Amtagvi launch and the maturation of the ATC network, why was specific numerical revenue guidance for 2026 excluded from this print, and when should the market expect it?
NSCLC Enrollment Ramp
With the FDA Fast Track designation in hand, how many of the target ~80 patients have been enrolled in the IOV-LUN-202 trial, and what is the specific timeline for data presentation in 2026?